Robert LeBoyer

Stock Analyst at Noble Capital Markets

(1.19)
# 3,725
Out of 5,163 analysts
18
Total ratings
31.25%
Success rate
-0.75%
Average return

Stocks Rated by Robert LeBoyer

Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $13.24
Upside: +428.70%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $3.73
Upside: +248.53%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150$250
Current: $1.72
Upside: +14,434.88%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $6.83
Upside: +778.48%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $7.40
Upside: +710.81%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.69
Upside: +271.75%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.53
Upside: +815.03%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.61
Upside: +396.89%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.25
Upside: +47,900.00%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $11.75
Upside: -
Initiates: Buy
Price Target: $12
Current: $4.65
Upside: +158.06%
Initiates: Buy
Price Target: $9,900,000
Current: $2.44
Upside: +405,737,604.92%
Downgrades: Neutral
Price Target: n/a
Current: $33.28
Upside: -
Initiates: Buy
Price Target: $15
Current: $2.99
Upside: +401.67%